Tang et al., 2016 - Google Patents
A modular vaccine development platform based on sortase-mediated site-specific tagging of antigens onto virus-like particlesTang et al., 2016
View HTML- Document ID
- 6075062672136514411
- Author
- Tang S
- Xuan B
- Ye X
- Huang Z
- Qian Z
- Publication year
- Publication venue
- Scientific reports
External Links
Snippet
Virus-like particles (VLPs) can be used as powerful nanoscale weapons to fight against virus infection. In addition to direct use as vaccines, VLPs have been extensively exploited as platforms on which to display foreign antigens for prophylactic vaccination and …
- 239000000427 antigen 0 title abstract description 43
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
- A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
- A61K47/4833—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse Transcribing DNA Viruses
- C12N2730/00011—Reverse Transcribing DNA Viruses
- C12N2730/10011—Hepadnaviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tang et al. | A modular vaccine development platform based on sortase-mediated site-specific tagging of antigens onto virus-like particles | |
| Zhang et al. | A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone | |
| D Hill et al. | Engineering virus-like particles for antigen and drug delivery | |
| Charlton Hume et al. | Synthetic biology for bioengineering virus‐like particle vaccines | |
| Fougeroux et al. | Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity | |
| Brouwer et al. | Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle | |
| Jones | Recent advances in the molecular design of synthetic vaccines | |
| Brune et al. | Dual plug-and-display synthetic assembly using orthogonal reactive proteins for twin antigen immunization | |
| Walker et al. | SplitCore: an exceptionally versatile viral nanoparticle for native whole protein display regardless of 3D structure | |
| Schwarz et al. | Viruslike particles encapsidating respiratory syncytial virus M and M2 proteins induce robust T cell responses | |
| Whitacre et al. | Use of hepadnavirus core proteins as vaccine platforms | |
| AU2001266163B2 (en) | Modification of hepatitis b core antigen | |
| McCormick et al. | Genetically engineered Tobacco mosaic virus as nanoparticle vaccines | |
| Ionescu et al. | Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier | |
| Strods et al. | Preparation by alkaline treatment and detailed characterisation of empty hepatitis B virus core particles for vaccine and gene therapy applications | |
| Andersson et al. | SnoopLigase peptide-peptide conjugation enables modular vaccine assembly | |
| Peyret et al. | Covalent protein display on Hepatitis B core-like particles in plants through the in vivo use of the SpyTag/SpyCatcher system | |
| Lei et al. | Genetic engineering strategies for construction of multivalent chimeric VLPs vaccines | |
| Wizemann et al. | Purification of E. coli-expressed HIS-tagged hepatitis B core antigen by Ni2+-chelate affinity chromatography | |
| Ulrich et al. | New chimaeric hepatitis B virus core particles carrying hantavirus (serotype Puumala) epitopes: immunogenicity and protection against virus challenge | |
| Kang et al. | Immunization with a self-assembled nanoparticle vaccine elicits potent neutralizing antibody responses against EBV infection | |
| Bugli et al. | Synthesis and characterization of different immunogenic viral nanoconstructs from rotavirus VP6 inner capsid protein | |
| Chuan et al. | Effects of pre‐existing anti‐carrier immunity and antigenic element multiplicity on efficacy of a modular virus‐like particle vaccine | |
| Cielens et al. | Mosaic RNA phage VLPs carrying domain III of the West Nile virus E protein | |
| Venter et al. | Multivalent display of proteins on viral nanoparticles using molecular recognition and chemical ligation strategies |